1
|
Marti L, Ten J, Herreros M, Diaz N, Rodriguez-Arnedo A, Guerrero J, Ortiz J, Bernabeu A, Bernabeu R. O-099 The use of cumulus cells (CCs) to select spermatozoa for intracytoplasmic sperm injection improves blastocyst development and quality. Hum Reprod 2022. [DOI: 10.1093/humrep/deac105.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Is there a role for sperm selection based on the capacity to pass through cumulus oophorous column in improving the laboratory outcomes in ICSI cycles?
Summary answer
A higher rate of blastocyst formation and quality are obtained with the use of CCs to select spermatozoa for ICSI compared to conventional density gradients.
What is known already
The sperm selection for ICSI is an operator-dependent procedure based on sperm morphology and motility. ICSI bypasses all natural barriers of sperm selection, which may impact embryo development.
During natural fertilization, only the spermatozoa that pass-through cumulus cells will have the chance to fertilize the egg. Spermatozoa capable of traverse COCs have better morphology, higher chromatin integrity and greater acrosomal reaction. Hyaluronic acid is an important component of these cells and plays a key role in the selection of spermatozoa with intact DNA. However, there is scarce data regarding this selection method for ICSI on the development of the embryo.
Study design, size, duration
This is a prospective randomized sibling oocyte pilot study (February-December 2021). A total of 996 metaphase II (MII) oocytes were randomized into two groups. In the control group (Group 0, n = 489 MII), ICSI was performed with sperm selected by conventional density gradients. In the study group (Group 1, n = 507 MII) the oocytes were microinjected with sperm selected through CCs. The main outcome was blastocyst formation rate and quality. Reproductive results were analyzed as secondary outcomes.
Participants/materials, setting, methods
Ninety-eight couples undergoing ICSI (private center) with ≥6 fresh own MII obtained after ovarian stimulation, embryo culture until blastocyst stage and ejaculated sperm samples were included in the study.
All seminal samples were processed using density gradients and those in the study group were additionally passed through CCs (the patient's own CCs were used in all cases).
Fertilization and day 5 blastocyst formation rates were assessed. Embryo quality was scored according to Gardner's criteria.
Main results and the role of chance
Data was similar with regards to cause of infertility, maternal age (36.47 vs 36.63 y.o.), sperm count (60.53 vs 58.25 mill/ml) and progressive motility (57.45 vs 57.50%) between group 0 vs 1, respectively.
Fertilization rate was similar between groups (74.0% vs 78.7%; p = 0.419. Group 0 vs 1, respectively). However, the blastocyst formation rate was significantly higher in the study group compared to control (70.9% vs 60.1%; p = 0.002). In addition, high-quality blastocyst rate was significantly higher in the CCs compared to the control group (49.6% vs 38.5%; p = 0.003). After the analysis of 145 treatments (131 frozen vs 14 fresh transfers) the cumulative clinical pregnancy rate in the study group was 47.2%, higher than in the control group (32.1%), but without reaching statistical difference (p = 0.07).
Limitations, reasons for caution
This is an exploratory study, aimed to evaluate the effectiveness of CCs as a more “physiologic” selection of spermatozoa for ICSI treatments in terms of laboratory outcomes (blastocyst formation rate and quality). Albeit not reaching statistical significance, the higher cumulative pregnancy rate in the study group seems clinically relevant.
Wider implications of the findings
Our results suggest that CCs can select more competent sperm for ICSI. This “physiologic-resembling”, operator-independent selection method has the potential of increasing pregnancy outcomes in ICSI cycles, pending of confirmation in larger studies including cumulative embryo-transfer cycles.
Trial registration number
NA
Collapse
Affiliation(s)
- L Marti
- Instituto Bernabeu, Embriology, Alicante , Spain
| | - J Ten
- Instituto Bernabeu, Embriology, Alicante , Spain
| | - M Herreros
- Instituto Bernabeu, Embriology, Alicante , Spain
| | - N Diaz
- Instituto Bernabeu, Embriology, Alicante , Spain
| | | | - J Guerrero
- Instituto Bernabeu, Embriology, Alicante , Spain
| | - J.A Ortiz
- Instituto Bernabeu Biotech, Molecular laboratory, Alicante , Spain
| | - A Bernabeu
- Instituto Bernabeu, Reproductive medicine, Alicante , Spain
| | - R Bernabeu
- Instituto Bernabeu, Reproductive medicine, Alicante , Spain
| |
Collapse
|
2
|
McIntyre C, McLeod M, Tutt T, Petersen A, Lepori-Bui N, Patel S, Monterola G, Siddiqui A, Villar K, Tran C, Bainter C, Pham T, Diaz N, Lim L, Dibian Z, Wang L, Meyer E. Process Development and Manufacturing: GROWING A CELL THERAPY FACILITY TO SUPPORT SPONSORED CLINICAL TRIALS AND COMMERCIAL CELL THERAPY PRODUCTS. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00449-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
3
|
Tutt T, Pham T, Brown A, Chinnasamy H, Feldman S, Egeler E, Patel S, Majzner R, Mackall C, Monje M, McLeod M, Lepori-Bui N, Villar K, Siddiqui A, Diaz N, Sukle N, McIntyre C, Meyer E. Regulatory Affairs, Quality Systems, Policy, and Ethics: INVESTIGATING PARTICULATES IN CELLULAR THERAPY PRODUCTS. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00486-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Xavierselvan M, Cook J, Duong J, Diaz N, Homan K, Mallidi S. Photoacoustic nanodroplets for oxygen enhanced photodynamic therapy of cancer. Photoacoustics 2022; 25:100306. [PMID: 34917471 PMCID: PMC8666552 DOI: 10.1016/j.pacs.2021.100306] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 09/07/2021] [Accepted: 09/21/2021] [Indexed: 05/20/2023]
Abstract
Photodynamic therapy (PDT) is a well-known cancer therapy that utilizes light to excite a photosensitizer and generate cytotoxic reactive oxygen species (ROS). The efficacy of PDT primarily depends on the photosensitizer and oxygen concentration in the tumor. Hypoxia in solid tumors promotes treatment resistance, resulting in poor PDT outcomes. Hence, there is a need to combat hypoxia while delivering sufficient photosensitizer to the tumor for ROS generation. Here we showcase our unique theranostic perfluorocarbon nanodroplets as a triple agent carrier for oxygen, photosensitizer, and indocyanine green that enables light triggered spatiotemporal delivery of oxygen to the tumors. We evaluated the characteristics of the nanodroplets and validated their ability to deliver oxygen via photoacoustic monitoring of blood oxygen saturation and subsequent PDT efficacy in a murine subcutaneous tumor model. The imaging results were validated with an oxygen sensing probe, which showed a 9.1 fold increase in oxygen content inside the tumor, following systemic administration of the nanodroplets. These results were also confirmed with immunofluorescence. In vivo studies showed that nanodroplets held higher rates of treatment efficacy than a clinically available benzoporphyrin derivative formulation. Histological analysis showed higher necrotic area within the tumor with perfluoropentane nanodroplets. Overall, the photoacoustic nanodroplets can significantly enhance image-guided PDT and has demonstrated substantial potential as a valid theranostic option for patient-specific photodynamic therapy-based treatments.
Collapse
Key Words
- 1O2, singlet oxygen
- BPD, benzoporphyrin derivative
- DLS, dynamic light scattering
- DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
- DSPE-mPEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
- H&E, hematoxylin and eosin
- HbT, total hemoglobin
- Hypoxia
- ICG, indocyanine green
- IF, immunofluorescence
- Image guided PDT
- MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- NIR, near infrared radiation
- PA, photoacoustic
- PBS, phosphate buffered saline
- PDT, photodynamic therapy
- PFC, perfluorocarbon
- PFP, perfluoropentane
- PS, photosensitizer
- Perfluorocarbon nanodroplets
- Photoacoustic imaging
- Photodynamic therapy
- ROS, reactive oxygen species
- SOSG, singlet oxygen sensor green
- StO2, oxygen saturation
- TBAI, tertbutylammonium iodide
- pO2, partial pressure of oxygen
Collapse
Affiliation(s)
- Marvin Xavierselvan
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
| | | | - Jeanne Duong
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
| | - Nashielli Diaz
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
| | | | - Srivalleesha Mallidi
- Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
- Corresponding author at: Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
| |
Collapse
|
5
|
Diaz N. American Heart Association (AHA) Scientific Sessions - 2021 Annual Meeting. Virtual - November 13-15, 2021. DRUG FUTURE 2022. [DOI: 10.1358/dof.2022.47.3.3393248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Catania G, Dal Molin A, Diaz N, Bagnasco A, Zanini M, Aleo G, Grosso D, Montalti S, Caldara C, Sperlinga R, Lacamera A, Zeneli A, Sasso L. Quality of informed consent in clinical trials patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz274.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Ruiz M, Mesplet F, Alonso J, Diaz N, Di Masi SA, Cox W, Arriola S, Rebora J, Farina J, Terusi A, Cusmano L, Viteri A, Zugasti N, Shimank E, Ezcurra M. Infection control program in elderly adults center. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
8
|
Torres JA, Mesplet F, Arriola S, Ruiz M, Andino S, Cox W, Diaz N, Herrera J, Liliana C, Farina J, Rebora J, Terusi A, Viteri A, Ezcurra M. Osteoarticular Implant Infections by Candida spp., experience at an elderly adults’ center. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3938] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
9
|
Arriola S, Ruiz M, Cox W, Masi SAD, Diaz N, Alonso J, Mesplet F, Zugasti N, Cusmano L, Farina J, Rebora J, Terusi A, Viteri A, Ezcurra M. Analysis of postoperative spinal surgery infections at an elderly care center. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.4309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
10
|
Larruskain J, Lekue JA, Diaz N, Odriozola A, Gil SM. A comparison of injuries in elite male and female football players: A five-season prospective study. Scand J Med Sci Sports 2017; 28:237-245. [PMID: 28207979 DOI: 10.1111/sms.12860] [Citation(s) in RCA: 110] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/13/2017] [Indexed: 11/30/2022]
Abstract
The aim was to compare the epidemiology of injuries between elite male and female football players from the same club. Injuries and individual exposure time in a male team and a female team, both playing in the Spanish first division, were prospectively recorded by the club's medical staff for five seasons (2010-2015) following the FIFA consensus statement. Total, training, and match exposure hours per player-season were 20% higher for men compared to women (P<.01). Total, training, and match injury incidence were 30%-40% higher in men (P≤.04) mainly due to a 4.82 (95% confidence interval [CI] 2.30-10.08) times higher incidence of contusions, as there were no differences in the incidence of muscle and joint/ligament injuries (P≥.44). The total number of absence days was 21% larger in women owing to a 5.36 (95% CI 1.11-25.79) times higher incidence of severe knee and ankle ligament injuries. Hamstring strains and pubalgia cases were 1.93 (95% CI 1.16-3.20) and 11.10 (95% CI 1.48-83.44) times more frequent in men, respectively; whereas quadriceps strains, anterior cruciate ligament ruptures, and ankle syndesmosis injuries were 2.25 (95% CI 1.22-4.17), 4.59 (95% CI 0.93-22.76), and 5.36 (95% CI 1.11-25.79) times more common in women, respectively. In conclusion, prevention strategies should be tailored to the needs of male and female football players, with men more predisposed to hamstring strains and hip/groin injuries, and women to quadriceps strains and severe knee and ankle ligament injuries.
Collapse
Affiliation(s)
- J Larruskain
- Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - J A Lekue
- Medical Services, Athletic Club, Lezama, Spain.,Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - N Diaz
- Medical Services, Athletic Club, Lezama, Spain
| | - A Odriozola
- Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - S M Gil
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| |
Collapse
|
11
|
Diaz N. 10th International Meeting of the International Society for the Study of Xenobiotics (ISSX), Toronto, Canada - September 29-October 3, 2013. DRUG FUTURE 2013. [DOI: 10.1358/dof.2013.038.12.2086994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Almenar-Cubells D, ROIG CB, Jimenez E, Cruz MÁ, Cuervo JM, Diaz N, Sánchez AB, Galan A, Giner V, Codes M. Daily G-CSFs versus pegfilgrastim (PEG) in cancer patients (pts) undergoing chemotherapy (CT): A multivariate analysis from clinical practice. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Esquerdo G, Cervera JM, Barrajon E, Juarez A, Llorca C, Diaz N, Lopez A, Peiro R, Diez L. Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors: Pronost study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Donovan S, Lim C, Diaz N, Browner N, Rose P, Sudarsky L, Tarsy D, Fahn S, Simon D. Laserlight cues for gait freezing in Parkinson’s disease: An open-label study. Parkinsonism Relat Disord 2011; 17:240-5. [DOI: 10.1016/j.parkreldis.2010.08.010] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2010] [Revised: 06/07/2010] [Accepted: 08/06/2010] [Indexed: 10/19/2022]
|
15
|
Blancas I, Morales S, Diaz N, Barnadas A, Gonzalvez ML, del Barco S, Lopez de Ceballos MH, Perez FJ, Llombart-Cussac A. Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1090] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Gonzalvez ML, Diaz N, Redondo A, Calvo EG, Illarramendi JJ, Munarriz B, Del Campo J, Castellanos Diez J, Santaballa A, Lopez-Vivanco G. Epidemiologic study to evaluate the treatment of palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e12014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Lopez Jimenez A, Esquerdo G, Barrajon E, Del Rio Pazos L, Cervera J, Diaz N, Angeles Oyonarte C. Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL) with CPT-11: A retrospective analysis. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Esquerdo G, Cervera J, Barrajon E, Juarez A, Llorca C, Diaz N, Lopez A, Peiro R. Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors (Pronost Study). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Castro AS, Xu J, Pereira DC, Ferre L, Diaz N, Moreno J, Du F. 169 EMBRYO TRANSFER OF SEXED/VITRIFIED IVF EMBRYOS IN CATTLE: PREGNANCY COMPARISON AFTER SINGLE AND DOUBLE TRANSFERS. Reprod Fertil Dev 2010. [DOI: 10.1071/rdv22n1ab169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Advancement in sperm sorting technology combined with vitrification of in vitro produced bovine embryos will promote cattle breeding and production. The objective of this study was to evaluate pregnancy and embryo loss after embryo transfer (ET) of sexed/vitrified embryos with one bilaterally (double transfer, 2 embryos) v. ipsilaterally (single transfer, 1 embryo) into the recipient. Bovine oocytes collected from slaughterhouse ovaries or ovum pickup were matured for 20-22 h, then subjected to IVF using Brackett and Oliphant BO procedures with sorted X-sperm, and cultured with our standard culture system. Expanded blastocysts with tight compaction of the inner cell mass (quality 1) were selected on Day 7 for cryopreservation via liquid nitrogen surface vitrification (LNSV; Xu et al. 2006 J. Dairy Sci. 89, 2510-2518). Embryo transfer was performed for 3 replicates in Navasota, Texas, in April 2009. Prior to ET, embryos were warmed and subsequently washed several times in warming, dehydration solution and base medium. Some of sexed/vitrified embryos were cultured for 3 days post-warming to determine the survivability. The treatments were as follows: (1) vitrified-single transfers, 1 embryo was transferred into the horn ipsilateral to CL; (2) vitrified-double transfers, 1 embryo was transferred into each uterine horn by nonsurgical transfer; and (3) fresh-single, 1 fresh embryo was transferred into the horn ipsilateral to CL (control) to a synchronous recipient on Day 7. Pregnancy was determined by ultrasound monitoring on Day 35, and palpation per rectum on Day 75 after transfer. The pregnancy data were analyzed by General Linear Model analysis (SPSS 11.0, SPSS Inc., Chicago, IL, USA). The survival rate of vitrified IVF embryos reached to as high as 97.6% (n = 42) 2 h post-warming, and hatching rate was 85.7% after 3 days culture in vitro. The data (Table 1) showed that there was no difference in Day 35 pregnancy rate among vitrified-double, vitrified-single, and fresh ET control groups. However, on Day 75 post-ET, there was a significantly higher fetal loss found in the vitrified-double transfer group (41.1%) compared to those of vitrified-single transfers (16.6%) and fresh-single group (11.9%) (P < 0.05). The pregnancy rate on Day 75 of 51.4% achieved with vitrified-single transfers was comparable to the 43.3% achieved with the fresh-single control transfers but was significantly higher than the 31.1% of the vitrified-double transfer group. This study demonstrated that double embryo transfers can aggravate high fetal loss and/or abortion when sexed IVF embryos are transferred, and ET with 1 sexed/vitrified embryo per recipient is sufficient to establish satisfactory pregnancy, comparable to that achieved with fresh embryos.
Table 1.Pregnancy and fetal loss of sexed/vitrified bovine IVF embryos following single and double transfers
Supported by USDA/CSREES-SBIR: 2006-03069 Phase II to F. Du.
Collapse
|
20
|
Jimenez-Fabrega X, Escalada-Roig X, Miro O, Sanclemente G, Diaz N, Gomez X, Villena O, Rodriguez E, Gaspar A, Molina JE, Salvador J, Sanchez M. Comparison between exclusively school teacher-based and mixed school teacher and healthcare provider-based programme on basic cardiopulmonary resuscitation for secondary schools. Emerg Med J 2009; 26:648-52. [DOI: 10.1136/emj.2008.062992] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Cervera JM, Garcia-Carbonero I, Girones R, Beltran M, Calderero V, Gonzalvez ML, Domenech M, Diaz N, Jimenez-Lacave P, Gonzalez A. Clinical experience with oral vinorelbine (NVB) plus prednisone as first- or second-line chemotherapy of metastatic hormone- refractory prostate cancer (HRPC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16151 Background: IV NVB plus hydrocortisone (HC) compared with HC alone resulted in improved clinical benefit, progression-free survival (PFS) and PSA response rate in HRPC. The oral formulation of NVB avoids the side effects associated with the IV injection, may reduce administration and toxicity-related costs and is easy to administer. Due to these advantages, single agent oral NVB treatment could be considered as an optimal option for patients (p) with HRPC previously treated with a taxane or as first-line treatment when a taxane is not indicated. We retrospectively evaluated efficacy and toxicity or oral NVB administered as single agent as first or second-line chemotherapy of metastatic HRPC. Methods: Retrospectively data was collected from p with metastatic HRPC treated with oral NVB 80 mg/m2 days 1 and 8, with a prior test of myelosensitivity at 60 mg/m2 for the first cycle, plus prednisone 10 mg/day. Patients had received a taxane as first-line treatment or had a documented contraindication to receiving docetaxel. 1 cycle was equivalent to a 3-week period. Results: Data on 55 p treated in 11 Spanish centres were included for assessment. Median age was 72.5 years (range 54–86). ECOG PS 0, 17%; 1, 66%; 2, 17%. Median PSA 75 ng/mL. Prior taxane chemotherapy, 87%. Median number of cycles was 4 (range 1–6). 53.8% of p could escalate oral NVB to 80 mg/m2. 221 cycles were performed, 4.1% were delayed and 3.2% had a dose reduction. Grade 3–4 events were infrequent and mainly haematological: neutropenia (5.5% of p), anemia (3.6%), pain (3.6%), infection (1.8%), asthenia (1.8%), respiratory (1.8%). No febrile neutropenia was reported. 49 p were evaluable for PSA response rate; complete plus partial response was observed in 20.4% (95% CI: 10.2% - 34.3%) and PSA stable was reported in 40.8%. 29 p were evaluable for measurable disease; among them, 20.7% presented partial response and 44.8% stable disease. Median follow-up was 4.3 months. Survival status: 49 p (89.1%) are alive and 6 p (10.9%) died. Conclusions: Oral NVB is a safe and active regimen in previous chemotherapy treated HRPC. For those p who can not receive a taxane as first-line therapy, oral NVB can also be considered as an effective first-line treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. M. Cervera
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - I. Garcia-Carbonero
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - R. Girones
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - M. Beltran
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - V. Calderero
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - M. L. Gonzalvez
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - M. Domenech
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - N. Diaz
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - P. Jimenez-Lacave
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| | - A. Gonzalez
- Hospital General de Elda, Elda, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Lluis Alcanys, Xativa, Spain; ICO, Hospital Dr. Josep Trueta, Girona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Fundacio Althaia, Manresa, Spain; Hospital Universitario San Juan, San Juan de Alicante, Spain; Hospital Universitario Central de Asturias, Oviedo, Spain; Hospital Universitario Son Dureta, Palma de Mallorca, Spain
| |
Collapse
|
22
|
Graul A, Revel L, Barrionuevo M, Cruces E, Rosa E, Vergés C, Lupone B, Diaz N, Castañer R. The year's new drugs & biologics - 2008. ACTA ACUST UNITED AC 2009; 22:7-29. [DOI: 10.1358/dnp.2009.22.1.1303754] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
23
|
Lopez R, Menendez M, Diaz N, Suarez D, Campomanes P, Ardura D, Sordo T. Theoretical Studies on the Ring Opening of β-lactams: Processes in Solution and in Enzymatic Media. CURR ORG CHEM 2006. [DOI: 10.2174/138527206776818883] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
24
|
Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley M, Gewert C, Howard C, Sack RB, Sack DA, Chang HS, Gomes G, Bourgeois AL. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine 2006; 24:3709-18. [PMID: 16153753 DOI: 10.1016/j.vaccine.2005.07.022] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
In the present study we compared the ELISPOT and antibody in lymphocyte supernatants (ALS) assays as surrogate measures of mucosal immunity. In separate studies, 20 inpatient volunteers received oral doses of 6 x 10(8) or 4 x 10(9)cfu of ETEC strain E24377A (LT+, ST+, CS1+, CS3+) and 20 subjects received 1 (n = 9) or 2 (n = 11) oral doses of the attenuated ETEC vaccine, PTL-003 expressing CFA/II (CS1+ and CS3+) (2 x 10(9)cfu/dose). Peripheral blood mononuclear cells (PBMCs) from all subjects were assayed for anti-colonization factor or toxin-specific IgA antibody responses using the ALS and ELISPOT procedures. ALS responses were measured using a standard ELISA, as well as by time-resolved fluorescence (TRF). Following challenge with E24377A, significant anti-CS3, CS1 and LT ALS responses were detected in the lymphocyte supernatants of 75-95% of the subjects. A similar proportion (75%) of subjects mounted an ALS response to CFA/II antigen after vaccination with the PTL-003 vaccine. Inter-assay comparisons between ALS and ELISPOT methods also revealed a high degree of correlation in both immunization groups. ALS sensitivity versus the ELISPOT assay for LT, CS3 and CS1-specific responses following challenge were 95%, 94% and 78%, respectively and 83% for the ALS response to CFA/II antigen after vaccination with PTL-003. Correlation coefficients for the LT and CS3 antigens were 0.94 (p<0.001) and 0.82 (p<0.001), respectively after challenge and 0.78 (p<0.001) after vaccination. The association between ALS and ELISPOT for the CS1 antigen was however, significant only when ALS supernatants were tested by TRF (r = 0.91, p<0.001). These results demonstrate the value and flexibility of the ALS assay as an alternative to ELISPOT for the measurement of mucosal immune responses to ETEC antigens, particularly when the complexities of ELISPOT may make it impractical to perform.
Collapse
Affiliation(s)
- C M Carpenter
- Center for Immunization Research, Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 624 N. Broadway, HH, Rm 205, Baltimore, MD 21205, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Moulder SL, Munster P, Minton S, Diaz N, Horton J, Rocha Lima C, Hutson L, Sullivan D. Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. L. Moulder
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| | - P. Munster
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| | - S. Minton
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| | - N. Diaz
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| | - J. Horton
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| | - C. Rocha Lima
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| | - L. Hutson
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| | - D. Sullivan
- H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Univ of Miami and Sylvester Cancer Ctr, Miami, FL
| |
Collapse
|
26
|
Saigi E, Batiste-Alentorn E, Diaz N, Galan A, Salud A, Campos JM, Losa F, Gallen M, Massuti B, Asensio D. Phase II study of weekly irinotecan (CPT-11) associated to protracted oral tegafur (TGF) in previously untreated, advanced colorectal cancer (ACRC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Saigi
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - E. Batiste-Alentorn
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - N. Diaz
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - A. Galan
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - A. Salud
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - J. M. Campos
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - F. Losa
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - M. Gallen
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - B. Massuti
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - D. Asensio
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| |
Collapse
|
27
|
Quezada M, Varas F, Ruiz A, Islas A, Diaz N, Lecocq C. Detección inmunohistoquímica del antígeno del virus del síndrome respiratorio y reproductivo (vPRRS) en cerdos inoculados. ACTA ACUST UNITED AC 2004. [DOI: 10.4067/s0301-732x2004000200009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Sanchez M, Jimenez S, Diaz N, Miro O. Basic cardiopulmonary resuscitation program for high school students (PROCES): How many concepts and skills remain one year later? Ann Emerg Med 2004. [DOI: 10.1016/j.annemergmed.2004.07.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
29
|
Sanchez M, Jimenez S, Diaz N, Miro O. Basic cardiopulmonary resuscitation program for high school students (PROCES): Results from the pilot program. Ann Emerg Med 2004. [DOI: 10.1016/j.annemergmed.2004.07.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Imaz MS, Comini MA, Zerbini E, Sequeira MD, Spoletti MJ, Etchart AA, Pagano HJ, Bonifasich E, Diaz N, Claus JD, Singh M. Evaluation of the diagnostic value of measuring IgG, IgM and IgA antibodies to the recombinant 16-kilodalton antigen of mycobacterium tuberculosis in childhood tuberculosis. Int J Tuberc Lung Dis 2001; 5:1036-43. [PMID: 11716340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023] Open
Abstract
OBJECTIVE To evaluate the usefulness of the recombinant 16-kDa antigen (re-Ag16) of Mycobacterium tuberculosis in the serodiagnosis of tuberculosis (TB) in children. MATERIALS Seventy-four children with active TB, 49 apparently healthy contact children and 149 children suffering from non-mycobacterial diseases were evaluated. Detection of anti 16-kDa antigen IgG, IgM and IgA was performed by enzyme-immunoassay. RESULTS An increased mean antibody response to re-Ag16 was observed in contact children compared with non-mycobacterial disease patients (IgG assay: 89.1 enzymatic units [eu] vs. 40.8 eu; IgM assay: 64.7 eu vs. 38.1 eu; IgA assay: 138.2 eu vs. 78.2 eu for contact children and non-mycobacterial disease patients, respectively), indicating that anti-16-kDa antibodies could be elevated in response to infections even without clinically apparent TB. Setting the specificity as the 95th percentile of the contact group's ELISA units, the sensitivity of the IgG, IgA and IgM assays were 34%, 19% and 3% respectively; combining results of the IgG and IgA assays led to 43% positivity in children with active TB. CONCLUSION The detection of anti 16-kDa IgG and IgA may be useful as a complementary technique for the diagnosis of childhood TB. Recognition of this antigen seems to be heterogeneous; combining responses against other antigens may be a good strategy to improve the performance of this assay.
Collapse
Affiliation(s)
- M S Imaz
- Instituto Nacional de Enfermedades Respiratorias Emilio Coni, ANLIS C. Malbran, Santa Fe, Argentina.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Levert V, Derbekyan V, Alkahtani A, Diaz N. Aneurysm of the distal descending thoracic aorta causing a pulmonary perfusion defect. Clin Nucl Med 2001; 26:948-9. [PMID: 11595855 DOI: 10.1097/00003072-200111000-00017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- V Levert
- Department of Nuclear Medicine, Royal Victoria Hospital, Montreal, Quebec, Canada
| | | | | | | |
Collapse
|
32
|
van den Nieuwenhof IM, Renardel de Lavalette C, Diaz N, van Die I, van den Berg TK. Differential galactosylation of neuronal and haematopoietic signal regulatory protein-(α) determines its cellular binding-specificity. J Cell Sci 2001; 114:1321-9. [PMID: 11256998 DOI: 10.1242/jcs.114.7.1321] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Signal regulatory protein-(α) (SIRP(α)) is a member of the Ig superfamily selectively expressed by neuronal and myeloid cells. The molecule mediates functional interactions with CD47/integrin-associated protein. Here we provide evidence for the tissue-specific glycosylation of neuronal and haematopoietic SIRP(α). We demonstrate a major difference in the galactosylation of N-linked glycans isolated from neuronal (i.e. brain-derived) SIRP(α) as compared to myeloid (i.e. spleen-derived) SIRP(α), with neuronal SIRP(α) almost completely lacking galactose. (β)4-galactosyltransferase assays demonstrated that this is most likely due to a low galactosylation capacity of the brain. In order to investigate the role of galactosylation of SIRP(α) in cellular interactions, soluble recombinant SIRP(α) glycoforms containing galactose (SIRP(α)-Fc) or lacking galactose (SIRP(α)((Δ)Gal)-Fc) were produced. Binding studies demonstrated superior binding of SIRP(α)((Δ)Gal)-Fc to cerebellar neurons and isolated lymphocytes. In contrast, SIRP(α)-Fc bound relatively strong to macrophages. These data show that the galactosylation of SIRP(α) determines its cellular binding specificity.
Collapse
Affiliation(s)
- I M van den Nieuwenhof
- Department of Medical Chemistry, Research Institute Immunology and Inflammatory diseases, Vrije Universiteit, Van der Boechorststraat 7, The Netherlands.
| | | | | | | | | |
Collapse
|
33
|
Ripalda JM, Diaz N, Roman E, Galan L, Montero I, Goldoni A, Baraldi A, Lizzit S, Comelli G, Paolucci G. Chemical shift resolved photoionization cross sections of amorphous carbon nitride. Phys Rev Lett 2000; 85:2132-2135. [PMID: 10970480 DOI: 10.1103/physrevlett.85.2132] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2000] [Indexed: 05/23/2023]
Abstract
The various components in the N 1s photoemission spectra of amorphous carbon nitride are identified by measuring their photon energy dependence and comparing the experimental results with ab initio multiple scattering calculations. The intensity modulations with photon energy are due to the extended x-ray absorption fine structure effects.
Collapse
Affiliation(s)
- JM Ripalda
- Departamento de Fisica Aplicada, Universidad Autonoma de Madrid, Madrid 28049, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Mouse spleen lymphocyte (SL) cells show a three to four-fold increase in [3H]-thymidine incorporation when incubated in tumour cell media, or in media containing tumour cell cytosol. Agarose gel chromatography of both [3H]-thymidine-labelled tumour cell media and cytosol shows a sharp peak of DNA-associated material eluting at about 60 kDa. This DNA-associated material is imported rapidly and efficiently by SL cells and is recoverable from their cytosol. The stimulating effect on SL cell thymidine incorporation resides primarily, if not exclusively, in this extruded/cytosolic 60 kDa DNA material. Tumour cells incubated in media containing normal or liver, but not tumour, cytosol show a reduced rate of [3H]-thymidine incorporation, indicating competition between normal and tumour associated DNA complexes. The results indicate that such cell-extruded DNA complexes may transmit 'genetic messages' to other cells, and are discussed in terms of interactions in the tumour-bearing host.
Collapse
Affiliation(s)
- D H Adams
- Life Sciences Division, King's College London, U.K
| | | | | |
Collapse
|
35
|
Abstract
Mouse spleen lymphocyte (SL) cells show a three to four-fold increase in [3H]-thymidine incorporation when incubated in tumour cell media, or in media containing tumour cell cytosol. Agarose gel chromatography of both [3H]-thymidine-labelled tumour cell media and cytosol shows a sharp peak of DNA-associated material eluting at about 60 kDa. This DNA-associated material is imported rapidly and efficiently by SL cells and is recoverable from their cytosol. The stimulating effect on SL cell thymidine incorporation resides primarily, if not exclusively, in this extruded/cytosolic 60 kDa DNA material. Tumour cells incubated in media containing normal or liver, but not tumour, cytosol show a reduced rate of [3H]-thymidine incorporation, indicating competition between normal and tumour associated DNA complexes. The results indicate that such cell-extruded DNA complexes may transmit 'genetic messages' to other cells, and are discussed in terms of interactions in the tumour-bearing host.
Collapse
Affiliation(s)
- D H Adams
- Life Sciences Division, King's College London, U.K
| | | | | |
Collapse
|
36
|
Diaz N, Khoury A, Taboada M, Isava I, Calderon A, Lopez C, Casale E, Romer H. [Primary intestinal lymphangiectasia in children. Report of 3 cases]. G E N 1995; 49:307-9. [PMID: 8762662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
It report three cases of Primary Intestinal Lymphangiectasia that presented the common symptoms of diarrhea, oedema and hipoalbuminaemia in which we could observed the clinics variations that can to present this entity. It demonstrated the importance of the intestinal biopsy to get a correct diagnosis just as the essencial of use of the medium chain triglycerides with the restriction of the common fast, to recuperate these patients.
Collapse
Affiliation(s)
- N Diaz
- Servicio de Gastroenterología, Hospital de Niños J.M. de Los Ríos
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Boissel JP, Némoz C, Gillet J, Salewski B, Diaz N. [Drug prescription in myocardial postinfarction: results of the EPPI (étude de prescription postinfarctus). A French cooperative study]. Arch Mal Coeur Vaiss 1990; 83:1777-82. [PMID: 1980055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
An enquiry into the prescribing behaviour in patients discharged from hospital after myocardial infarction was performed in 36 hospital departments in France and included 528 patients. Each patient was prescribed an average of 3.6 drugs. The most commonly prescribed drug was Aspirin (63.3%) followed by the calcium antagonists (61.7%) long acting nitrate derivatives (49.5%) and betablockers (41.5%). These results suggest that many post-infarction prescriptions disregard recently acquired scientific knowledge.
Collapse
|
38
|
Sanchez G, Wallace A, Olivares M, Diaz N, Aguilera X, Apt W, Solari A. Biological characterization of Trypanosoma cruzi zymodemes: in vitro differentiation of epimastigotes and infectivity of culture metacyclic trypomastigotes to mice. Exp Parasitol 1990; 71:125-33. [PMID: 2113007 DOI: 10.1016/0014-4894(90)90015-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Thirty-one Trypanosoma cruzi isolates from Chile, Peru, and Bolivia were studied in their capacity to differentiate in vitro from epimastigotes to metacyclic trypomastigotes on TAU-3AAG medium. Zymodeme 1 parasites displayed the best level of differentiation, which ranges from 60 to 90% depending on the isolate. Zymodeme 2 parasites exhibited highly heterogenous differentiation rates. This differentiation method permits the obtention of large amounts of metacyclic trypomastigotes from zymodeme 1 parasites. Metacyclic trypomastigotes obtained in vitro were infective to nude Balb/c hybrid mice. Zymodeme 1 parasites produced high parasitemias in this murine model; in contrast, zymodeme 2 parasites displayed lower parasitemias. Of a total of 27 T. cruzi isolates, 20 proved to be infective to mice, 12 gave enough parasites for further studies, and 8 of these were used for biological characterization. Results are compared with the infective clone Dm28 and Tulahuén strains maintained since 1954 in mice.
Collapse
Affiliation(s)
- G Sanchez
- Department of Biochemistry, Faculty of Medicine, University of Chile, Santiago
| | | | | | | | | | | | | |
Collapse
|
39
|
Domínguez JP, Amenábar E, Mendoza F, Pivet H, Palacios L, Lagos A, Diaz N, Calderón J, Cardenas R, Pérez-Olea J. [Hepatic drug monitoring in patients exposed to antitubercular treatment]. Rev Med Chil 1982; 110:733-7. [PMID: 7156604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
40
|
Diaz N. [The rural emergency dispensary (discussion with rural pharmacists)]. Rev Sanid Hig Publica (Madr) 1969; 43:103-5. [PMID: 5407295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|